Mainz Biomed B.V. (MYNZ)

Develops biopharmaceuticals for autoimmune diseases and oncology, focusing on innovative treatments and biologics.

MYNZ Stock Quote

Company Report

Mainz Biomed B.V., located in Mainz, Germany, is a pioneering molecular genetics cancer diagnostic company specializing in the development of advanced in-vitro diagnostic (IVD) and research use only tests for clinical applications in human genetics. Established in 2008, Mainz Biomed is dedicated to enhancing healthcare outcomes through innovative diagnostic solutions.

The company's product portfolio includes ColoAlert, a cutting-edge colorectal cancer screening test, and PancAlert, a promising candidate for pancreatic cancer screening. Additionally, Mainz Biomed offers GenoStrip, a molecular genetic-based tool designed to detect pathogens in various environments. Its range of offerings encompasses both research-use-only tests and IVD tests, underscoring its commitment to providing accurate and reliable diagnostic tools.

Driven by a commitment to scientific excellence and clinical utility, Mainz Biomed continues to advance its capabilities in molecular genetics diagnostics. With a strategic focus on improving early detection and treatment outcomes for cancer and other genetic disorders, the company remains at the forefront of diagnostic innovation in the healthcare industry.

MYNZ EPS Chart

MYNZ Revenue Chart

Stock Research

LFWD PERI GRVY ISTR FRGE FORD DRH

MYNZ Chart

View interactive chart for MYNZ

MYNZ Profile

MYNZ News

Analyst Ratings